FDA investigating deaths of patients who had gastric balloon procedure for obesity

August 11, 2017 by Melissa Healy, Los Angeles Times

The U.S. Food and Drug Administration has alerted physicians and surgeons who treat obesity that it is investigating whether there is a link between gastric balloons - a new-generation weight-loss device - and the deaths of five patients.

In an alert issued Thursday, the FDA said that from 2016 to the present, five "unanticipated deaths" had occurred within a month or less in patients who had liquid-filled gastric systems implanted in their stomachs. In three of the cases, the agency said that patients died between one and three days after the weight-loss device had been put in place.

"At this time, we do not know the root cause or incidence rate of patient death, nor have we been able to definitively attribute the deaths to the devices or the insertion procedures for these devices," the FDA told physicians.

The agency suggested it would explore the possibility that patients suffered gastric and esophageal perforation or intestinal obstruction, either while the device was being implanted or afterward.

Four of the deaths involved the Orbera Intragastric Balloon System, manufactured by Apollo Endo Surgery of Austin, Texas, and approved by the FDA in August 2015. One of the reports involved the ReShape Integrated Dual Balloon System, manufactured by ReShape Medical Inc. in San Clemente, Calif., and approved by the FDA in July 2015.

The agency said it has received reports of two other deaths since 2016 related to potential complications associated with balloon treatment. In one of those deaths, a patient who had the Orbera Intragastric Balloon System implanted suffered a gastric perforation. In the second death a patient who got the ReShape Integrated Dual Balloon System suffered an esophageal perforation.

The manufacturers of both devices have not responded to the Los Angeles Times' efforts to seek comment.

The FDA's new scrutiny of the weight-loss devices follows earlier safety concerns conveyed to health care providers. In February, the agency warned that it had received reports of adverse event in which liquid-filled gastric balloons, once in patients' stomachs, overinflated with air or liquid - a phenomenon it called spontaneous hyperinflation. The problem required removal of the device ahead of schedule.

The agency also said it had received reports that patients getting the devices developed , which also resulted in the need for early removal of the balloons.

Stanford bariatric surgeon Dr. John Morton, who has implanted roughly 70 of the ReShape devices, said he has not seen complications in his patients, who have typically lost weight with the devices.

"Every death is a tragedy, and has to be investigated," said Morton, who is a past president of the American Society for Metabolic and Bariatric Surgery. But as devices used for patients at relatively low levels of obesity, and which promote relatively modest weight loss, the standard of safety they should meet is particularly high, he added.

Both the ReShape and Orbera systems are approved for patients with a body-mass index, or BMI, between 30 and 40. They are generally considered a less invasive and less costly alternative to for patients who are less obese or cannot tolerate permanent surgical alteration of their gastrointestinal tract.

"I can only speculate this is likely to do with technique," Morton said. "There's skill involved in the placement of these balloons. Who places them makes a difference. If you're an experienced endoscopist and surgeon you recognize the signs of perforation, which is important, because they're treatable."

Gastric balloons are delivered into the stomach via the mouth in an outpatient procedure considered "minimally invasive." The procedure generally takes less than 30 minutes, during which a patient is under mild sedation. They are designed to be in place for six months.

Once in place, the balloon is inflated with a sterile solution, which takes up room in the stomach. While nausea and stomach discomfort are expected in the days immediately following the procedure, those symptoms typically abate. While the devices are in place, patients who get them are expected to feel less hungry and typically report losing between 5 percent and 10 percent of their weight.

Apollo's website says that more than 220,000 people worldwide have had its weight-loss balloon implanted. International sales of gastric balloons were estimated to total about $120 million in 2015, driven by broad use in Brazil, Mexico and Europe.

But Morton said that manufacturers report only about 5,000 gastric balloons have been implanted in the United States. The American Society for Metabolic and Bariatric Surgery says facilities it has accredited to perform the procedures have implanted about 1,000 of the devices, and recently reported they have seen no deaths due to complications.

"These devices need to be placed in centers that have adequate follow-up, the resources to provide that follow-up, and the experience to recognize these complications," Morton said.

The FDA said Thursday it "continues to work with Apollo Endo-Surgery and ReShape Medical Inc. to better understand the issue of unanticipated , and to monitor the potential complications of acute pancreatitis and spontaneous overinflation."

The agency said it "will communicate publicly when we have new information to share." In the meantime, the agency said, " should speak to their doctors to determine which obesity treatment option is best for them."

Explore further: FDA issues warning about balloon obesity treatments

Related Stories

FDA issues warning about balloon obesity treatments

February 13, 2017
(HealthDay)—Fluid-filled balloons placed in the stomach to treat obesity have been linked to serious complications, the U.S. Food and Drug Administration reports.

'Balloon-in-a-pill' spurs weight loss, health benefits: study

May 8, 2017
(HealthDay)—A new type of "balloon-in-a-pill" may offer a nonsurgical way for obese people to shed pounds—and get healthier, too, a small study hints.

A balloon for obesity: an option between medication and surgery?

November 10, 2014
For many struggling with obesity, taking one of the newly approved prescription medications for weight loss (marketed as Qsymia, Belviq and Contrave) feels like climbing a mountain with a walking cane - it's a little help, ...

FDA approves stomach-filling balloon for weight loss

July 28, 2015
Federal health regulators on Tuesday approved an inflatable medical balloon that aids weight loss by filling up space in the stomach.

Swallowable balloons work to curb obesity: study

May 18, 2017
Weight-loss balloons swallowed rather than surgically inserted in the stomach were shown to be safe and effective in preliminary trials, according to findings unveiled Thursday at a medical conference.

New endoscopic, non-surgical bariatric options show promise for treating obesity

August 7, 2015
The FDA recently approved two new endoscopic bariatric therapies (EBT) for the treatment of obesity. According to the American Society for Gastrointestinal Endoscopy (ASGE), this development provides important new, minimally ...

Recommended for you

Study adds to evidence that most prescribed opioid pills go unused

August 2, 2017
In a review of half a dozen published studies in which patients self-reported use of opioids prescribed to them after surgery, researchers at Johns Hopkins report that a substantial majority of patients used only some or ...

Engineers harness the power of 3-D printing to help train surgeons, shorten surgery times

August 2, 2017
A team of engineers and pediatric orthopedic surgeons are using 3D printing to help train surgeons and shorten surgeries for the most common hip disorder found in children ages 9 to 16. In a recent study, researchers showed ...

World's first child hand transplant a 'success'

July 19, 2017
The first child in the world to undergo a double hand transplant is now able to write, feed and dress himself, doctors said Tuesday, declaring the ground-breaking operation a success after 18 months.

Knee surgery—have we been doing it wrong?

July 18, 2017
A team of University at Buffalo medical doctors have published a study that challenges a surgical practice used for decades during arthroscopic knee surgery.

New tools help surgeons find liver tumors, not nick blood vessels

July 17, 2017
The liver is a particularly squishy, slippery organ, prone to shifting both deadly tumors and life-preserving blood vessels by inches between the time they're discovered on a CT scan and when the patient is lying on an operating ...

Researchers discover indicator of lung transplant rejection

July 13, 2017
Research by scientists at Dignity Health St. Joseph's Hospital and Medical Center's Norton Thoracic Institute was published in the July 12, 2017 issue of Science Translational Medicine titled "Zbtb7a induction in alveolar ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.